Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Anneke Zeillemaker"'
Publikováno v:
British Journal of Medical and Health Research. 5:26-34
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9836e9da30914bcbd3a2040287316a1f
https://doi.org/10.46624/bjmhr.2018.v5.i03.002
https://doi.org/10.46624/bjmhr.2018.v5.i03.002
Autor:
Stefan Böhringer, Dirk Jan A.R. Moes, Henk-Jan Guchelaar, Maartje Los, Carolien H. Smorenburg, Hans Gelderblom, Vincent O. Dezentjé, Patrick Neven, Edith van Druten, Lynn Jongen, Erdogan Batman, Jesse J. Swen, A B Sanchez-Spitman, Aart van Bochove, Anneke Zeillemaker
Publikováno v:
Journal of Clinical Oncology, 37(8), 636
PURPOSE Tamoxifen is widely prescribed as adjuvant therapy in patients with early-stage breast cancer. It has been postulated that concentrations of endoxifen, the active metabolite of tamoxifen, are a better predictor of tamoxifen efficacy than CYP2
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::78af074106d5afd069289678ab2ec826
https://hdl.handle.net/1887/120026
https://hdl.handle.net/1887/120026
Publikováno v:
European Journal of Trauma and Emergency Surgery. 35:74-78
A compartment syndrome is an increased tissue pressure within a closed osteofascial compartment. This compromises blood flow to the muscles and nerves within that compartment, which -if not treated adequately in an early stage-results in permanent ti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::765477090cfa5a013d14289af6b78c79
https://doi.org/10.1007/s00068-008-8026-8
https://doi.org/10.1007/s00068-008-8026-8
Autor:
Carolien H. Smorenburg, Jan den Hartigh, Erdogan Batman, Henk-Jan Guchelaar, Trees J. Hessing, E. Maartense, Maartje Los, Hein Putter, Hans Gelderblom, Philomeen Kuijer, Frans L. Opdam, Tahar van der Straaten, Patrick Neven, J.W.R. Nortier, Robert Vree, Vincent O. Dezentjé, Anne-Sophie Dieudonné, Cornelis J.H. van de Velde, Jan A.C. Brakenhoff, Anneke Zeillemaker
Publikováno v:
Journal of Clinical Oncology. 31:595-595
595 Background: Breast cancer patients with absent or reduced CYP2D6 activity may benefit less from tamoxifen treatment because of impaired biotransformation to the active metabolite endoxifen. We investigated whether a temporary one-step dose escala
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4243135a56d2f0540130e6a4f5538f22
https://doi.org/10.1200/jco.2013.31.15_suppl.595
https://doi.org/10.1200/jco.2013.31.15_suppl.595